Dimerix (ASX:DXB) has announced that the US FDA has given conditional approval for the brand name QYTOVRA for its Phase 3 clinical drug candidate.
US FDA grants conditional approval to the brand name of Dimerix's DMX-200
September 25, 2023 Australian Biotech
Latest Video
New Stories
-
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Bellberry announces new appointment to board of directors
July 27, 2026 - - Latest News -
The power of this commitment might be as a comparison of national intent
July 27, 2026 - - Latest News -
New AI platform aims to give patients a strong voice in medicines funding
July 27, 2026 - - Latest News

